April 4, 2025 07:00 AM EDT
Peer Review

No­vo Nordisk ad­justs its lead­er­ship team; Dyne alums mi­grate to Cres­cent Bio­phar­ma

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Kyle LaHucik

Senior Reporter

→ Camil­la Sylvest has moved on from No­vo Nordisk af­ter 28 years with the Dan­ish phar­ma, in­clud­ing more than sev­en years as EVP of com­mer­cial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bris­tol My­ers CEO sig­nals deal­mak­ing will be a top pri­or­i­ty in 2025

Drug­mak­ers see a sub­stan­tial, but man­age­able, hit to busi­ness from tar­iffs. But the worst may lie ahead

Roche CEO warns that tar­iffs could im­pact deal­mak­ing

Ver­san­t's lat­est biotech fo­cus­es on in­flam­ma­to­ry dis­eases

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times